Rubicon Research Ltd Q1 FY27 Earnings Call Summary

Revenue

Margin

Demand

Guidance

Tone

Metrics raised 1

FY27 EBITDA margin guidance raised to 23% (from 22-23%)

Event Participants

Executives

3 Parag Suganchand, Executives, Nitin Jajodia, Sagar Oak

Analysts

6 Akshay, Harsh Kundnani, Nishant Maheshwari, Prateek Shrivastava, Siddharth Negandhi, Tushar Manudhane

Financials & KPIs

Metric	Reported	Commentary
Revenue from Operations	₹534 crores	+52% YoY; broad-based growth; USD revenue $55M (+32% YoY) with slight QoQ dip from tactical exit of lower-margin business
Gross Profit	₹354 crores	+46% YoY; gross margin 67.7%, +140 bps QoQ despite higher input costs/freight due to geopolitical conditions
EBITDA	₹129 crores	+63.2% YoY; margin 24.2% vs 22.4% YoY and 23.1% QoQ
Pre-R&D EBITDA Margin	35%	vs 32.5% in Q1 FY26; reflects operational leverage
R&D Expense	₹58 crores	10.9% of revenue vs ₹35.5 crores in Q1 FY26; on track with ₹500 crore 9-quarter cumulative guidance
PAT	₹85 crores	+96% YoY; includes one-off insurance claim (goods lost in transit) in other income
EPS	₹5.08
USD Revenue	$55 million	+32% YoY from $42M; sequential dip due to tactical measures around lower-margin contracts; Q2 tracking strong
Operating Cash Flow	₹28.5 crores	Delayed GST refunds impacted quarter; expected to normalize in Q2 FY27
Net Working Capital	114 days	vs 126 days at 31 Mar 26; management guides normal range of 125-130 days
ROIC	36%	Sustained strong return despite ~25% of capital employed in pre-revenue investments (Pitampur, New Jersey, Arena)

Geographic & Segment Commentary

US Business (Core): USD revenue of $55 million in Q1, up 32% YoY; sequential decline from tactical exit of lower-margin contracts - management confirmed Q2 FY27 is tracking strong for sequential USD revenue recovery. Pricing remains stable due to specialty and differentiated product focus.
Specialty Portfolio: Contributed 36% of gross profit for the quarter; gross margin improved 140 bps QoQ to 67.7% despite input cost and freight escalation, driven by mix shift toward high-value differentiated products with 0-1 competitors.
Arena Life Sciences (Acquired April 2026): Contributed ~₹12 crores revenue in Q1 with no material EBITDA impact; management following a phased approach - fixing growth levers in FY27, then beating IPM growth, with profitability last.
Manufacturing Facilities: Pitampur (30-acre site, only 5-6 acres utilized) resolved FDA 483 with two procedural observations and received approval on a regulatory filing post-inspection; commercial operations on track for Q1 CY2027. New Jersey (East Brunswick) site acquired for $2.9M with VAI classification from May 2026 FDA inspection; adjacent to AMRX3PL distribution, enabling onshore US manufacturing for specialty and government business; commercialization expected CY2027.

Company-Specific & Strategic Commentary

New Jersey Acquisition: Acquired a US FDA-regulated manufacturing facility in East Brunswick via court-supervised bankruptcy for $2.9 million - a fraction of replacement cost. Site shares a wall with existing distribution operations (AMRX3PL) and is near US headquarters; post-May 2026 inspection status is VAI (voluntary action). Management sees this as margin-accretive, not dilutive, enabling government/VA business and supply chain risk diversification.
R&D Investment Program: On track for cumulative ₹500 crores over 9 quarters through Q1 FY28; ₹251 crores spent across 5 quarters at ~₹60 crores per quarter. R&D as % of revenue maintained at 10-11% (industry-leading); R&D productivity currently at 5.5x multiple based on Q1 FY27 annualized revenue, excluding Arena.
EBITDA Guidance Revision: Raised FY27 EBITDA margin guidance to 23% (from 22-23%) despite known headwinds - ESOP costs from new scheme, Arena kickstart costs, and pre-revenue costs for New Jersey and Pitampur facilities.
Organizational Restructuring: Nitin Jajodia (CFO) transitioning to Chief Commercial Officer role; Rohit appointed CFO designate and will assume CFO role post-transition; supports management bandwidth for next growth phase.
Strategic Facilities Rationale: Multi-site footprint driven by portfolio needs - Ambarnath (oral solids/nasal sprays), Satara (liquids, nasal backups), Pitampur (hormones, steroids, high-potent, large capacity), CSN (modular-ready for niche dosage forms), plus US site for onshore capability.

Guidance & Outlook

Metric	Guidance / Outlook	Commentary
EBITDA Margin	23% for FY27 (revised up from 22-23%)	Reflects tactical exit of lower-margin business; offsets ESOP costs, Arena growth investments, pre-revenue facility costs
R&D Spend	₹500 crores cumulative through Q1 FY28	₹251 crores spent in 5 quarters; current run rate ₹60 crores/quarter; on track
R&D as % of Revenue	10-11% sustained	FY27 is final year of tapering absolute R&D spend; increasing spend impact visible from FY28
Pitampur Commercialization	Q1 CY2027	FDA 483 resolved (2 procedural observations); regulatory filing approved post-inspection
New Jersey Facility Commercialization	CY2027	After implementing quality management systems at the site
Working Capital	125-130 days range	Q1 reported 114 days but this reflects quarterly fluctuations, not a structural change
Q2 FY27 Revenue	Sequentially higher USD revenue	Management confirms strong tracking for sequential USD revenue growth

Risks & Constraints

Risk	Context
Input Cost & Freight Inflation	Sharp increase in input costs and freight due to geopolitical conditions continued in Q1, pressuring gross margins; management partially offset through tactical portfolio mix shift toward specialty products; remains a watch item for FY27
GST Refund Delays	Delayed GST refunds impacted Q1 operating cash flow (₹28.5 crores vs pre-WC change of ₹139 crores); management expects normalization and healthy cash flow in Q2
Regulatory / FDA Compliance	FDA conducted unannounced inspection at Pitampur (July) - resolved with 2 procedural observations; New Jersey site had initial 483 with 6 observations, subsequently classified VAI. Both resolved, but ongoing regulatory scrutiny remains for new site integrations
US Tariff Exposure	~97% of exports go to US; analyst flagged potential tariff risk - management did not directly address but noted onshore manufacturing in New Jersey as mitigation and risk diversification
EBITDA Margin Diluents	ESOP costs under new scheme, Arena growth kickstart costs, and pre-revenue costs for New Jersey and Pitampur facilities are specific FY27 cost impacts; still guiding 23% margin
Arena Execution	Acquisition closed April 2026 with ₹12 crores Q1 revenue and no material EBITDA; phase 1 (fixing growth levers) ongoing - profitability expected only in later phases

Q&A Highlights

Product Portfolio & Growth Maturity

Question: What therapeutic areas and maturity stages are the top products in, and how should we expect larger TAM products to commercialize? (Akshay, AK Investment)
Answer: Portfolio is broad-based with concentration declining - top 5 products at 39% and top 10 at 55% of revenue, broadly in line with last 4 quarters. Products launched 8-10 years ago continue to show strong growth (including those showcased in IPO). At DRHP/RHP filing, 60+ products were at advanced stages with 63 at RHP time. Management does not comment on product-level pipeline specifics as commercially sensitive. (Nitin Jajodia, Parag Suganchand, Sagar Oak)

Does AI Improve R&D Efficiency?

Question: Is AI improving product development cycle efficiency and business processes? (Akshay, AK Investment)
Answer: Management views AI, automation as technology adopted wherever it adds value - increasing efficiency, compliance, and reducing errors. However in regulated pharma settings, regulators must be given confidence that technology has enough checks and balances for consistent, predictable, robust results. AI is a large evolving field - cannot comment specifically. (Parag Suganchand)

Approvals Pace & Fewer-Bigger Strategy

Question: Approvals seem to be slowing down while revenue growth is healthy - is this a fewer, bigger strategy? (Siddharth Negandhi, Chanakya Wealth Creation)
Answer: Approvals are in line with the plan and forecast; management is conservative in building revenue forecasts. It is not fewer approvals and bigger numbers - still a clear portfolio strategy. Number of approvals is only indicative; company is on track with approvals on which the plan is built. (Parag Suganchand)

New Jersey Facility - Margin Impact

Question: How should manufacturing footprint play out between US and India, and what is gross margin impact? (Siddharth Negandhi, Chanakya Wealth Creation)
Answer: US facility is a strategic move - enables government/VA business, proximity to customers, flexibility for strategic products, and adjacency to distribution operations. Margins should not be diluted and should be accretive overall. Strategic value: customers view dual-site supply (India + US) positively and could command premium. (Nitin Jajodia, Parag Suganchand)

Specialty Portfolio Disclosures

Question: What is the churn and count of specialty products (0-1 competitor)? (Siddharth Negandhi, Chanakya Wealth Creation)
Answer: Disclosures are deliberately balanced to track investors without jeopardizing competitive position - share of gross profit from specialty shared once a year; management will not expand specialty disclosure set. (Sagar Oak)

Pitampur Capacity Headroom

Question: What does "headroom for expansion" mean at Pitampur? (Siddharth Negandhi, Chanakya Wealth Creation)
Answer: Pitampur is a ~30-acre site of which only 5-6 acres are currently utilized - greater footprint than all other sites combined. Expanding incrementally is feasible; enough capacity for both near-term scale-up (9-12 months) and long-term growth. CSN facility is modularly ready for niche dosage forms. (Sagar Oak, Parag Suganchand)

Transfer Pricing & Revenue-Input Costs Math

Question: With additional input costs of ~₹38 crores (materials + purchases) and inventory changes, how did revenue jump ₹181.9 crores - is there transfer pricing inflation? Also how will US tariffs be managed? (Nishant Maheshwari, Growealth)
Answer: Management is fully compliant with transfer pricing norms - no change in transfer pricing mechanism. Standalone vs consolidated inventory differences involve mix of own manufacturing, outsourced manufacturing, and traded goods. Gross margin impact in recent quarters reflects higher reliance on outsourced manufacturing. Suggested connecting offline to walk through specific math. On tariffs: no direct response - Hmm actually looking back at the transcript, the management didn't really answer the tariff question directly. They only addressed the transfer pricing and margins math. (Nitin Jajodia)

Arena Contribution & Margin Implications

Question: Clarify Arena's revenue contribution (₹12 crores) and EBITDA impact - does that mean base business margins are higher than reported? (Harsh Kundnani, Aionios Alpha)
Answer: Revenue ~₹12 crores with no material EBITDA contribution; with that small a revenue base, there is a slight dilution of overall margin - so base business margins are slightly higher than reported, but not material by order of magnitude. (Parag Suganchand, Sagar Oak)

Arena Phased Growth Approach

Question: How do you see Arena's margins going forward? (Harsh Kundnani, Aionios Alpha)
Answer: Arena business is being built in phases - Phase 1 (FY27 focus): identify and fix growth levers; Phase 2: beat IPM growth and drive growth; Phase 3: profitability. Consolidated EBITDA guidance of 23% for FY27 already accounts for Arena growth investments. (Nitin Jajodia, Sagar Oak)

New Jersey Acquisition - How at $2.9M?

Question: How did you acquire a US manufacturing facility at just a couple of million dollars? (Tushar Manudhane, Motilal Oswal Financial Services)
Answer: Approach to M&A is patient, long-term value creation - this process ran well over 1.5 years through court-supervised bankruptcy. Existing adjacency (AMRX3PL distribution site) and ecosystem connection gave advantage. Past acquisitions (Canada center, Satara from Cipla) followed same disciplined approach - built multiple revenues and profitability on acquired capabilities. (Sagar Oak, Parag Suganchand)

R&D Quantum & Portfolio Approach

Question: Is the ₹500 crore R&D spend product-specific or spread across portfolio? (Tushar Manudhane, Motilal Oswal Financial Services)
Answer: Always portfolio-based approach across multiple parameters - risk probability, execution ease, organizational maturity, long-term high innovation products, and products with competitive advantage. Never concentrated on few big bets. (Parag Suganchand)

Rationale for Multiple Facilities

Question: Why so many facilities across so many sites? (Tushar Manudhane, Motilal Oswal Financial Services)
Answer: Each facility was acquired based on a pipeline thesis: Ambarnath (core - oral solids, nasal sprays), Satara (liquids in-house, nasal backup), Pitampur (hormones/steroids/high-potent, large batch sizes, continuous manufacturing), CSN (modular for niche dosage forms). Facilities provide risk diversification for business continuity and dual-sourcing for important products. Capex lags sales - facilities built based on revenue capability visibility. (Parag Suganchand)

US Revenue Decline & Replacement

Question: Did the lower-margin US business exit get replaced by higher-margin business? (Prateek Shrivastava, Nivesh Wisdom)
Answer: Yes - specialty share of overall gross profit has increased with revenue. Management exits lower-margin business only when securing higher-margin business. Gross margin improvement of 140 bps sequentially reflects this trade-off. (Nitin Jajodia, Sagar Oak)

Pitampur Capacity Utilization Curve

Question: What is the capacity utilization curve for Pitampur in 6-9 months vs 2-3 years? (Prateek Shrivastava, Nivesh Wisdom)
Answer: Commercial ramp-up starts Q1 CY2027 with gradual scaling over 9-12 months; near-term capacity is sufficient. Long-term: 30-acre site with only 5-6 acres used provides ample headroom for expansion. (Parag Suganchand)

FDA Filings Disclosure Cadence

Question: Last quarter you gave 24 products under FDA review - why is it missing this time? (Prateek Shrivastava, Nivesh Wisdom)
Answer: Previously communicated that this number will be shared once a year. Shared last quarter; will share again on annual cadence. (Nitin Jajodia)

Key Takeaway

Rubicon Research delivered a strong Q1 FY27 with consolidated revenue of ₹534 crores (+52% YoY), EBITDA of ₹129 crores (+63% YoY at 24.2% margin) and PAT of ₹85 crores (+96% YoY, including a one-off insurance claim), with gross margins improving 140 bps sequentially to 67.7% despite geopolitical input cost inflation. Strategic momentum was significant: Arena acquisition closed (₹12 crore Q1 revenue), New Jersey manufacturing site acquired for $2.9 million via bankruptcy with VAI FDA status, and Pitampur resolved its FDA 483 (2 procedural observations) with regulatory filing approved, keeping commercialization on track for Q1 CY2027. Management raised FY27 EBITDA guidance to 23% (from 22-23%) and confirmed R&D productivity at 5.5x with the ₹500 crore program on track (₹251 crores spent in 5 quarters). Key forward watchpoints include GST refund normalization in Q2, ongoing input cost/freight pressure, US tariff exposure (~97% of exports), and successful ramp-up of Arena, Pitampur, and New Jersey sites through CY2027.